Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
Volume 1.14M
Average 1.17M
BIIB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Biogen Inc.NASDAQ: BIIB
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation turns negative
Q2 FY2026 stock-based compensation was -$84M, compared with $74.9M a year earlier. Trailing-twelve-month stock-based compensation was $134.9M. Over 3 fiscal years it compounded at +4.6% a year.
Context
- Stock-based compensation amounted to 3.0% of revenue in FY2025, unchanged from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly stock-based compensation holds near -$84M or moves back toward the trailing-twelve-month quarterly average of $33.73M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 290.8M USD
- Year-over-year change
- -0.1%
- 4-year CAGR
- +5.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 290.8M | -0.1% |
| FY2024 | 2024-12-31 | 291.2M | +10.2% |
| FY2023 | 2023-12-31 | 264.2M | +4.0% |
| FY2022 | 2022-12-31 | 254.1M | +6.5% |
| FY2021 | 2021-12-31 | 238.6M | — |
Stock-Based Compensation vs competitors
How BIIB compares with its peers on the latest reported figures
- BIIB's LTM Jun 2026 stock-based compensation of $134.9M is the 8th largest of the 11 companies compared; the peer median is $414.31M.
- Its year-over-year change of -55.6% is the lowest of 10, against a peer median of +5.8%.
- Stock-based compensation amounts to 1.4% of revenue for BIIB, versus a peer median of 5.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $986.7M | -4.8% | +11.1% | 6.4% | |
| LTM Jun 2026 | $947M | +14.9% | -2.9% | 1.5% | |
| LTM Jun 2026 | $689.1M | +0.5% | +11.8% | 5.5% | |
| LTM Jun 2026 | $649.2M | +5.8% | +19.0% | 0.8% | |
| LTM Jun 2026 | $492M | -3.9% | +7.2% | 1.3% | |
| LTM Jun 2026 | $336.62M | +10.1% | +14.7% | 7.0% | |
| LTM Jun 2026 | $155.4M | +12.4% | +11.4% | 4.9% | |
| LTM Jun 2026 | $134.9M | -55.6% | +4.6% | 1.4% | |
| LTM Sep 2026 | $132.29M | +4.4% | +10.1% | 13.8% | |
| LTM Jun 2026 | $84.66M | +15.0% | -12.3% | 8.4% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BIIB) | $414.31M | +5.8% | +11.1% | 5.2% | |
Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.73B | 2.96B | 1.16B | 1.63B | 1.29B |
| Depreciation & Amortization | 487.7M | 518.4M | 494.8M | 673.2M | 779.9M |
| Deferred Income Tax | (426.8M) | (168.6M) | (305.8M) | (158.1M) | 361.6M |
| Stock-Based Compensation | 238.6M | 254.1M | 264.2M | 291.2M | 290.8M |
| Change in Working Capital | (145.5M) | (890.3M) | (648.7M) | (155.2M) | (1.06B) |
| Accounts Receivables | 326M | (222.4M) | 56.7M | 194.2M | 42.1M |
| Inventory | (462.4M) | (320.2M) | (130.9M) | (273.8M) | (64.7M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (9.1M) | (347.7M) | (574.5M) | (75.6M) | (1.04B) |
| Other Non-Cash Items | 1.76B | (1.29B) | 581.2M | 592.2M | 537M |
| Operating Cash Flow | 3.64B | 1.38B | 1.55B | 2.88B | 2.2B |
| Capital Expenditures | (258.1M) | (240.3M) | (311.4M) | (359.8M) | (153.8M) |
| Acquisitions (Net) | 28.1M | 595M | (6.91B) | (1.07B) | 0 |
| Purchases of Investments | (3.81B) | (3.45B) | (5.14B) | 0 | (1.26B) |
| Sales of Investments | 3.5B | 4.66B | 8.29B | 551.5M | 79.7M |
| Other Investing Activities | 12.9M | 24.4M | (11.3M) | 83.9M | (38.7M) |
| Investing Cash Flow | (563.7M) | 1.59B | (4.09B) | (799.2M) | (1.37B) |
| Debt Repayment | (170M) | (1B) | 187.3M | (650M) | (16.9M) |
| Common Stock Issued | (700K) | (1.9M) | (44.3M) | (31.3M) | (10M) |
| Common Stock Repurchased | (1.8B) | (750M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (115.5M) | (5.6M) | (6M) | (2.2M) | (275M) |
| Financing Cash Flow | (2.09B) | (1.76B) | 137M | (683.5M) | (301.9M) |
| Effect of Forex Changes | (59.8M) | (55.7M) | 35.1M | (67.7M) | 101.9M |
| Net Change in Cash | 930.2M | 1.16B | (2.37B) | 1.33B | 633.5M |
| Free Cash Flow | 3.38B | 1.14B | 1.24B | 2.52B | 2.05B |
Biogen Inc.
NASDAQ:BIIB
Intrinsic Alpha fair value
Locked
Current Price
$251.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.